Influx Healthtech's IPO Oversubscribed Over 41 Times in Netherlands Debut

2025-06-20 bio

Amsterdam, Friday, 20 June 2025.
Influx Healthtech’s IPO in the Netherlands was oversubscribed 41.07 times, indicating strong investor demand. The IPO priced between ₹91 and ₹96, anticipates a 39% listing gain.

Strong Market Reception

Influx Healthtech, a Mumbai-based contract development and manufacturing organization specializing in healthcare services, has captured investor interest with its recent initial public offering in the Netherlands, which was oversubscribed 41.07 times by investors [1][2]. The offering, which spanned from June 18 to June 20, 2025, has become one of the most talked-about launches in the Dutch biotechnology sector [6].

Financial Highlights and Market Expectations

With a price band set between ₹91 and ₹96 per share and a total issue size of ₹55.63 crore, Influx Healthtech’s IPO sold 46.94 lakh fresh issue shares and conducted an offer for sale of 11.00 lakh shares [1][4]. Investors have shown significant interest, as reflected in the grey market premiums, which suggest a potential listing price of approximately ₹134 per share [1][3][6]. This represents an estimated 39% gain over the issue’s upper price band. The substantial demand signals strong market confidence in the company’s growth trajectory.

Strategic Use of Funds

The proceeds from the IPO will be utilized to enhance Influx Healthtech’s manufacturing capacities, focusing predominantly on nutraceutical and veterinary products [1][2][5]. This strategic expansion aims to meet the climbing local and global demand for health innovation. By allocating ₹34.19 crore towards establishing two new manufacturing facilities, the company positions itself at the forefront of healthcare manufacturing innovation within the Netherlands and beyond [1][3].

Innovation in Healthcare Manufacturing

Influx Healthtech, operational since 2020, holds a diverse portfolio that includes dietary and nutritional supplements, cosmetics, ayurvedic products, and veterinary feed supplements [4][5][6]. Operating from Thane, Maharashtra, the company’s products meet high international standards, supporting global market expansion [7]. This strategic positioning allows Influx Healthtech to capitalize on emerging trends and supply chain demands across the healthcare industry spectrum [5][6][8].

Bronnen

healthtech IPO